# Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

> **NCT00866554** · PHASE2 · COMPLETED · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer
- Erectile Dysfunction
- Lower Urinary Tract Symptoms

## Interventions

- **DRUG:** administration of a LHRH agonist and Bicalutamide
- **DRUG:** administration of Bicalutamide, Dutasteride and Tamoxifen

## Key facts

- **NCT ID:** NCT00866554
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2019-03
- **Final completion:** 2019-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866554, "Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00866554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*